Author/Authors :
Zeinalian, Mehrdad Clinic of Gastrointestinal Diseases - Poursina Hakim Research Center - Isfahan University of Medical Sciences, Isfahan , Hashemzadeh-Chaleshtori, Morteza Clinic of Gastrointestinal Diseases - Poursina Hakim Research Center - Isfahan University of Medical Sciences, Isfahan , Salehi, Rasoul Clinic of Gastrointestinal Diseases - Poursina Hakim Research Center - Isfahan University of Medical Sciences, Isfahan , Kazemi, Mohammad Clinic of Gastrointestinal Diseases - Poursina Hakim Research Center - Isfahan University of Medical Sciences, Isfahan , Emami, Mohammad Hassan Clinic of Gastrointestinal Diseases - Poursina Hakim Research Center - Isfahan University of Medical Sciences, Isfahan
Abstract :
Background: Microsatellite instability (MSI) is a mutational signature that is the hallmark of Lynch syndrome, and MSI testing
is a cost-effective method to screen the disease. Since there is no enough data about MSI status and associated clinicopathologic
features of hereditary nonpolyposis colorectal cancer (HNPCC) in Iran, our study is a new trial to describe them in center of Iran
(Isfahan). Materials and Methods: It is a descriptive retrospective study to screen HNPCC families using Amsterdam II criteria
in Central Iran within 2000-2013. For MSI testing, we used a commercially available kit evaluating mononucleotide markers (BAT-
25, BAT-26, MON0-27, NR-21 and NR-24). After a fluorescent multiplex polymerase chain reaction amplification of the markers,
samples were sequenced to fragment analysis. Data analysis was performed using SPSS 16 software (SPSS Inc., Chicago, IL, USA).
Results: Overall, 31 of 45 screened HNPCC families were eventually included to MSI testing. Totally, 9/31 patients (29.0%) showed MSI
in their tumor tissues. BAT-26 was the most instable marker with instability in 7/24 MSI tumors (29.2%). The mean age at diagnosis
in microsatellite stable (MSS), MSI-Low (MSI-L), and MSI-High (MSI-H) probands was respectively 44.7 (standard deviation [SD]
= 11.83), 51.7 (SD = 16.17), and 36.0 (SD = 3.41) years. The most common tumor sites in MSS, MSI-L, and MSI-H probands were
rectosigmoid (~72.8%), rectum (66.7%) and right colon (50.0%), respectively. Of 186 cancer patients among 31 HNPCC families,
86 patients (46.2%) had colorectal cancer (CRC) and 100 patients (53.8%) had extracolonic cancers. The average of CRC affected
members among MSS, MSI-L, and MSI-H groups of our HNPCC families was 2.2 (SD = 1.30), 3.3 (SD = 3.21), and 4.7 (SD = 2.42)
patients per family, respectively. Stomach with 18.3% and 26.7% of all extracolonic cancers were most common involved organ in
MSS and MSI-H families, respectively. Conclusion: Our different molecular results could be suggested to describe HNPCC families
based on some new molecular mechanisms leading to MSS HNPCC phenotypes. Meanwhile, more evaluations within our population
are recommended.